Design of cancer assays for pharmaceutical agents.
作者信息
Meyers D B, Young S S, Gries C L
出版信息
J Natl Cancer Inst. 1985 May;74(5):1151-2.
PMID:3858583
Abstract
摘要
相似文献
1
Design of cancer assays for pharmaceutical agents.
J Natl Cancer Inst. 1985 May;74(5):1151-2.
2
Design of cancer assays for pharmaceutical agents: a reply.用于药物制剂的癌症检测方法设计：一则回应。
J Natl Cancer Inst. 1986 Aug;77(2):589-90.
3
[Carcinogenicity studies in experimental animals. II. Interpretation of the results and significance for man].[实验动物致癌性研究。II. 结果解读及对人类的意义]
Ned Tijdschr Geneeskd. 1986 Jun 7;130(23):1051-4.
4
Design of cancer assays for pharmaceutical agents.
J Natl Cancer Inst. 1984 Jun;72(6):1212.
5
Environmental cancer: animal studies and assay procedures.
Tex Rep Biol Med. 1978;37:45-9.
6
Comparison of carcinogenicity studies with aldrin and dieldrin.艾氏剂和狄氏剂致癌性研究的比较。
J Assoc Off Anal Chem. 1979 Jul;62(4):900-3.
7
8
Considerations in the interpretation of animal bioassays for chemical carcinogenicity.化学致癌性动物生物测定解释中的注意事项。
Transplant Proc. 1984 Apr;16(2):412-5.
9
Rationale for deployment of short-term assays for evidence of carcinogenicity.
IARC Monogr Eval Carcinog Risk Chem Hum Suppl. 1980(2 Suppl):295-308.
10
Future possibilities for shorter-term assays of carcinogenicity.短期致癌性检测的未来可能性。
Transplant Proc. 1984 Apr;16(2):403-5.
引用本文的文献
1
Issues of biochemical applications to risk assessment: how should the MTD be selected for chronic bioassays?生物化学应用于风险评估的问题：慢性生物测定中应如何选择最大耐受剂量（MTD）？
Environ Health Perspect. 1987 Dec;76:169-74. doi: 10.1289/ehp.8776169.
Zotero 插件